Medstorm Innovation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Medstorm Innovation - overview
Location
Oslo, -, Norway
Primary Industry
Medical Devices & Equipment
About
Medstorm Innovation develops advanced medical technology solutions, particularly the PainSensor device, which quantifies pain levels through skin conductance measurement, enhancing pain management in clinical settings. Medstorm Innovation is focused on creating innovative medical devices aimed at pain assessment. The company is headquartered in Oslo, Norway, and was founded by Hanne Storm, who is also the current CEO. In June 2007, Sarsia Seed invested in Medstorm, although specific financial terms were not disclosed.
Medstorm specializes in advanced medical technology, with its flagship product being the PainSensor device, a Class IIa skin conductance algesimeter. This device has been validated through over 80 peer-reviewed clinical studies for its ability to assess pain levels and nociceptive events by measuring skin sympathetic nerve activity. The PainSensor is designed for integration with existing monitoring systems and has CE certification, with plans for FDA approval to reach markets in the European Union and the United States healthcare system. In 2022, Medstorm Innovation generated a revenue of USD 499,647.
30 and reported an EBITDA of USD -348,596. 50. Revenue is primarily derived from sales of the PainSensor device and its software solutions to healthcare providers, utilizing a pricing model that reflects the necessity of effective pain management. Medstorm Innovation aims to enhance its product line with upcoming innovations, focusing on the PainSensor and its integration capabilities with additional monitoring systems.
The company has plans for geographic expansion, particularly targeting the United States market by leveraging its CE certification while pursuing FDA approval. Recent funding from the investment in June 2007 will support these growth initiatives, facilitating product development and market entry strategies.
Current Investors
Sarsia
Primary Industry
Medical Devices & Equipment
Sub Industries
Therapeutic Devices
Website
www.med-storm.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Medstorm Innovation - timeline of key events
Medstorm Innovation - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 807,045 | 1,094,514 | 1,397,142 | 1,028,313 | 261,438 | 847,652 | 311,693 | 1,007,150 | 2,666,374 | 584,070 | 2,717,957 | 1,183,224 | - | - | - |
| % Revenue Growth (YoY) | - | 35.6% | 27.6% | (26.4%) | (74.6%) | 224.2% | (63.2%) | 223.1% | 164.7% | (78.1%) | 365.3% | (56.5%) | - | - | - |
| EBITDA (USD) | (69,771) | 20,278 | (910,419) | (1,816,181) | (760,964) | 308,101 | (654,254) | 1,159,411 | (128,733) | 572,232 | (2,805,030) | (1,102,242) | - | - | - |
| Operating Income (USD) | (69,771) | 20,278 | (910,419) | (1,816,181) | (760,964) | 301,301 | (661,054) | 1,152,611 | (135,533) | 365,432 | (2,925,030) | (1,195,575) | - | - | - |
| Operating Margin | (8.6%) | 1.9% | (65.2%) | (176.6%) | (291.1%) | 35.5% | (212.1%) | 114.4% | (5.1%) | 62.6% | (107.6%) | (101.0%) | - | - | - |
| % EBITDA Margin | (8.6%) | 1.9% | (65.2%) | (176.6%) | (291.1%) | 36.3% | (209.9%) | 115.1% | (4.8%) | 98.0% | (103.2%) | (93.2%) | - | - | - |
| NET Income (USD) | (151,082) | (14,885) | (944,814) | (1,854,011) | (798,182) | 309,803 | (660,167) | 1,255,051 | (297,598) | 158,605 | (3,093,779) | (1,544,036) | - | - | - |
| % Net Margin | (18.7%) | (1.4%) | (67.6%) | (180.3%) | (305.3%) | 36.5% | (211.8%) | 124.6% | (11.2%) | 27.2% | (113.8%) | (130.5%) | - | - | - |
Medstorm Innovation - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | Medstorm Innovation | - |
Displaying 1 - 1 of 1
Medstorm Innovation - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.